🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Fortrea Holdings Inc. FTRE R2K

Healthcare · Biotechnology · United States
https://www.fortrea.com

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

READ MORE ›
$15.39
+257.91% 1Y

Market & Price

Market Cap
$1.46B
Current Price
$15.39
High / Low (52W)
$18.40 / $4.13
Beta
1.91

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
14.30
PEG Ratio
0.34
Book Value
$6.05
Price to Book
2.54
P/S
0.54
EV/EBITDA
34.72
Dividend Yield
-

Profitability & Returns

ROCE
-49.47%
ROE
-64.55%
ROA
-0.05%
Profit Margin
-16.50%
Op Margin
0.52%
EPS (Latest Qtr)
$-0.25
EPS (TTM)
$-4.81

Balance Sheet & Liquidity

Debt/Equity
2.13
Quick Ratio
0.83
Current Ratio
0.95
Debt
$1.12B
Total Assets
$2.72B
Current Assets
$897.20M
Working Capital
$-16.10M

Ownership

Promoter Holding
0.82%
Chg in Prom Hold
-
FII / Inst Holding
109.99%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$2.43B
Total Revenue (TTM)
$2.71B
EBITDA
$69.90M
Free Cash Flow
$285.61M
Operating Cash Flow
$220.70M
Shares Outstanding
94.58M
Gross Margin
18.86%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
-1.35%
Profit 5Y
-209.88%
Revenue (YoY)
-2.30%
Earnings (YoY)
-

PROS

  • Generates positive free cash flow.

CONS

  • Revenue declined at -1.4% CAGR over 5 years.
  • Earnings shrank at -209.9% CAGR over 5 years.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 FTRE Fortrea Holdings Inc. R2K 15.39 - $1.46B - -49.47% -64.55% -1.35% -209.88%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
⚙Ad space

Quarterly Results

Figures in USD.

Metric Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -793.10M762.30M693.90M725.10M713.80M662.10M662.40M--651.30M710.30M701.30M660.50M636.50M
Cost of Revenue ----------534.80M576.80M578.60M529.40M512.90M
Gross Profit ----------116.50M133.50M122.70M131.10M123.60M
Operating Expenses ----------141.30M144.40M126.40M122.30M120.30M
Operating Income -71.20M68.90M14.10M31.60M10.30M-37.40M-50.90M---24.80M-10.90M-3.70M8.80M3.30M
EBITDA -----------506.20M-327.80M13.50M6.90M26.60M
Interest Expense ----------22.30M23.30M22.60M23.20M19.10M
Pretax Income -----------548.00M-370.70M-28.70M-35.60M-12.30M
Tax Provision ----------14.90M4.20M-12.80M-3.10M11.30M
Net Income 32.50M66.40M60.60M12.50M30.80M-14.00M-101.00M-138.40M---562.90M-374.90M-15.90M-32.50M-23.60M
Diluted EPS -0.750.680.140.35-0.16-1.13-1.55---6.25-4.14-0.17-0.35-0.25

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 3.06B2.84B2.84B2.70B2.72B
Cost of Revenue -2.11B2.25B2.16B2.22B
Gross Profit -724.40M590.60M534.20M503.80M
Operating Expenses -501.60M537.40M646.00M534.40M
Operating Income 114.30M222.80M53.20M-111.80M-30.60M
EBITDA -280.80M137.20M-64.30M-813.60M
Interest Expense -200.00K69.70M123.80M91.40M
Pretax Income -187.00M-30.50M-275.00M-983.00M
Tax Provision -41.10M1.20M-3.50M3.20M
Net Income 98.00M186.20M-25.20M-328.50M-986.20M
Diluted EPS 1.102.11-0.04-3.67-10.81

Compounded Sales Growth

5 Years:-1.35%
1 Year:-2.30%

Compounded Profit Growth

5 Years:-209.88%
1 Year:-

Stock Price Performance

1 Year:+257.91%
6 Months:+20.42%
3 Months:+43.56%
1 Month:+45.74%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --4.29B4.33B3.58B2.72B
Current Assets --1.25B1.25B948.20M897.20M
Cash & Equivalents --112.00M108.60M118.50M174.60M
Inventory ------
Receivables --449.20M420.20M156.50M113.60M
Total Liabilities --945.30M2.62B2.22B2.15B
Current Liabilities --699.00M778.40M949.50M913.30M
Long Term Debt ---1.57B1.05B1.05B
Total Debt --63.40M1.67B1.20B1.12B
Total Equity 3.29B-3.34B1.71B1.36B563.50M
Shares Outstanding --88.80M88.80M89.70M93.10M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -82.70M168.40M262.80M113.50M
Investing Cash Flow --54.00M-31.80M251.60M14.40M
Financing Cash Flow --6.30M-140.80M-497.80M-76.30M
Capital Expenditure --54.40M-40.30M-25.50M-25.20M
Free Cash Flow -28.30M128.10M237.30M88.30M
Net Change in Cash -22.40M-4.20M16.60M51.60M

Ratios (Annual)

Figures in %.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -25.5%20.8%19.8%18.5%
Operating Margin % 3.7%7.9%1.9%-4.1%-1.1%
Net Margin % 3.2%6.6%-0.9%-12.2%-36.2%
ROE % -5.6%-1.5%-24.1%-175.0%
ROCE % -6.2%1.5%-4.3%-1.7%

Shareholding Pattern

Insiders
0.82%
Institutions
109.99%
Public Float
110.90%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 16.02% 15.15M $233.20M
2 Goldman Sachs Group Inc 8.56% 8.10M $124.64M
3 Corvex Management LP 4.91% 4.64M $71.47M
4 Sessa Capital IM, L.P. 4.86% 4.59M $70.69M
5 State Street Corporation 4.34% 4.11M $63.24M
6 Vanguard Capital Management LLC 4.27% 4.04M $62.15M
7 Vanguard Portfolio Management LLC 3.91% 3.70M $56.89M
8 AQR Capital Management, LLC 3.49% 3.30M $50.76M
9 Charles Schwab Investment Management, Inc. 3.39% 3.21M $49.37M
10 Deutsche Bank AG 2.72% 2.57M $39.54M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for FTRE

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space